<DOC>
	<DOCNO>NCT00004747</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess efficacy monthly intravenous mucoid exopolysaccharide Pseudomonas aeruginosa immune globulin ( MEP IGIV ) give 1 year reduce frequency acute pulmonary exacerbation patient cystic fibrosis , mild moderate pulmonary disease , mucoid P. aeruginosa colonization . II . Assess effect MEP IGIV FEV1 , sputum density mucoid P. aeruginosa , quality life patient . III . Assess safety monthly MEP IGIV . IV . Assess population-based MEP IGIV pharmacokinetics chronic therapy .</brief_summary>
	<brief_title>Phase II Randomized , Double-Blind , Placebo-Controlled Study Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin Cystic Fibrosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients stratify participate institution . Patients randomly assign 1 3 group : low-dose intravenous mucoid exopolysaccharide Pseudomonas aeruginosa immune globulin ( MEP IVIG ) , high-dose MEP IVIG , placebo . Therapy administer every 28 day 12 month . Treatment initiate presence acute asthmatic attack . Concurrent chronic suppressive antibiotic permit .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Cystic fibrosis ( CF ) document pilocarpine iontophoresis sweat chloride great 60 mEq/L FEV1 30 % 80 % predict within 20 % maximum value obtain 12 month prior entry Able expectorate least 1 g sputum within 3 hour screen Mucoid Pseudomonas aeruginosa colonization document least 2 serial expectorate sputum culture year prior entry Screening specimen meet requirement 1 culture Documented exacerbation respiratory tract infection At least 1 hospitalization and/or course parenteral nebulized antibiotic therapy 2 year prior entry At least 2 serial spirometry test least 6 month prior entry FEV1 range 15 % relative maximum value None follow within 6 month prior entry : Pseudomonas ( Burholderia ) cepacia atypical mycobacteria respiratory tract Pulmonary hemorrhage great 5 % drop hematocrit Pneumothorax require chest tube No lifethreatening CF sequela , e.g . : Severe cirrhosis ascites bleed Severe distal intestinal obstruction syndrome require cessation oral intake Poorly control insulindependent diabetes acetonuria Prior/Concurrent Therapy No concurrent participation investigational protocols No prior investigational P. aeruginosa vaccine At least 45 day since immune globulin antibacterial monoclonal antibody At least 4 week since investigational drug At least 2 week since systemic glucocorticoid No requirement systemic steroid first 2 week study Patient Characteristics Renal : Creatinine le 2 mg/dL ( 1.5 mg/dL patient 50 kg ) No proteinuria No hematuria Cardiovascular : No cor pulmonale heart disease require chronic diuretic , afterload reduction , cardiac glycoside therapy ( e.g. , digoxin ) Immunologic : Endogenous immunoreactive IgA least 5 mg/dL No hypersensitivity immune globulin human albumin No primary acquire immunodeficiency disease Other : No clinical test abnormal repeat inconsistent CF No smoke 1 month prior study No suspected drug alcohol abuse within 1 year prior entry No severe illness precludes protocol participation No disability , condition , geographical location would impair compliance No psychiatric disorder , intellectual deficiency , condition would limit informed consent Negative pregnancy test require fertile woman Medically acceptable contraception require fertile woman Participating investigator , subinvestigators , study coordinator , employee participate investigator immediate family member group ineligible Blood/body fluid analysis exams within 28 day prior registration</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>bacterial infection</keyword>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>